Neurothera Labs Inc. (C0A)
Market Closed
31 Jul, 20:00
XFRA 
€
0. 12
+0.01
+4.6809%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
- Eps
€ 0.12
Previous Close Want to track C0A and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
C0A closed Friday higher at €0.12, an increase of 4.6809% from Thursday's close, completing a monthly increase of 42.3611% or €0.04. Over the past 12 months, C0A stock gained 33.5505%.
C0A is not paying dividends to its shareholders.
The last earnings report, released on Mar 09, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 3 different exchanges and in various currencies, with the primary listing on TSX-V (CAD).
C0A Chart
Neurothera Labs Inc. (C0A) FAQ
What is the stock price today?
The current price is €0.12.
On which exchange is it traded?
Neurothera Labs Inc. is listed on XFRA.
What is its stock symbol?
The ticker symbol is C0A.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Neurothera Labs Inc. ever had a stock split?
No, there has never been a stock split.
Neurothera Labs Inc. Profile
| - Industry | - Sector | - CEO | XFRA Exchange | - ISIN |
| United States Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Neurothera Labs Inc. is a clinical-stage pharmaceutical company dedicated to creating cannabinoid-based treatments for neurological and neurodevelopmental disorders. Based in Vancouver, Canada, the company is actively advancing its drug development programs, which focus on both psychoactive THC and non-psychoactive CBD. Neurothera Labs Inc. is committed to addressing complex central nervous system disorders, with a particular emphasis on conditions that are often underserved by existing treatments. The company's innovative approach aims to translate current scientific research into therapeutic products that can improve patient outcomes in various challenging health areas.
Products and Services
- THC-based therapies: These treatments leverage the psychoactive properties of THC to target neurological conditions such as Tourette syndrome. By harnessing the therapeutic potential of THC, Neurothera Labs Inc. aims to offer alternative management solutions for patients contending with severe symptoms.
- CBD-based therapies: Focused on non-psychoactive applications, these therapies use CBD to treat multiple conditions, including Alzheimer’s disease and agitation. By avoiding the psychoactive effects, these products provide a safer option for patients, particularly for long-term management of chronic conditions.
- Autism Spectrum Disorder (ASD) treatments: Neurothera is developing treatments specifically for ASD, aimed at addressing behavioral issues and improving overall quality of life for affected individuals. This innovative approach may provide families with new hope where traditional therapies have fallen short.
- Status epilepticus interventions: The company is working on urgent treatment solutions for status epilepticus, a life-threatening condition. By focusing on rapid-acting cannabinoid compounds, Neurothera Labs Inc. seeks to develop timely and effective interventions that can stabilize patients in emergency situations.
- Research and development services: In addition to its proprietary therapies, Neurothera Labs engages in R&D services that utilize advanced scientific methods to investigate potential cannabinoid applications. This opens the door for partnerships and collaborations aimed at discovering new therapeutic avenues for complex conditions.
Contact Information
Address: 18 Shea Way
Phone: -
Website: https://www.neurothera.com
